Access cutting-edge lung cancer treatment through this clinical trial at a research site in Clermont. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Clermont at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this lung cancer clinical trial in Clermont, FL
If you're searching for lung cancer treatment options in Clermont, FL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Clermont research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.